GSK5764227 (HS-20093): Clinical Development of a Next-Generation HER2-Directed Antibody–Drug Conjugate
https://www.newsbeep.com/nz/262926/
HER2 remains one of the most therapeutically actionable oncogenic drivers in solid tumors, most prominently in breast and…
https://www.newsbeep.com/nz/262926/
HER2 remains one of the most therapeutically actionable oncogenic drivers in solid tumors, most prominently in breast and…
GSK5764227 (HS-20093): Clinical Development of a Next-Generation HER2-Directed Antibody–Drug Conjugate - New Zealand News Beep
HER2 remains one of the most therapeutically actionable oncogenic drivers in solid tumors, most prominently in breast and gastric cancers, and increasingly
www.newsbeep.com
February 1, 2026 at 8:45 PM
GSK5764227 (HS-20093): Clinical Development of a Next-Generation HER2-Directed Antibody–Drug Conjugate
https://www.newsbeep.com/nz/262926/
HER2 remains one of the most therapeutically actionable oncogenic drivers in solid tumors, most prominently in breast and…
https://www.newsbeep.com/nz/262926/
HER2 remains one of the most therapeutically actionable oncogenic drivers in solid tumors, most prominently in breast and…
Oncogenic HPV types identified in Paleolithic and Chalcolithic human genome sequencing data from Ust’-Ishim and Ötzi www.biorxiv.org/content/10.6...
www.biorxiv.org
February 1, 2026 at 8:26 PM
Oncogenic HPV types identified in Paleolithic and Chalcolithic human genome sequencing data from Ust’-Ishim and Ötzi www.biorxiv.org/content/10.6...
GSK5764227 (HS-20093): Clinical development of next generation HER2-directed antibody drug conjugate
HER2 remains one of the most therapeutic oncogenic drivers in solid tumors, most prominent in breast and tumors. stomach cancerFurthermore, it is increasingly being found across a wider range of…
HER2 remains one of the most therapeutic oncogenic drivers in solid tumors, most prominent in breast and tumors. stomach cancerFurthermore, it is increasingly being found across a wider range of…
GSK5764227 (HS-20093): Clinical development of next generation HER2-directed antibody drug conjugate
HER2 remains one of the most therapeutic oncogenic drivers in solid tumors, most prominent in breast and tumors. stomach cancerFurthermore, it is increasingly being found across a wider range of HER2-expressing or HER2-mutant malignancies, including: lung cancer. Although multiple HER2-targeted agents have already entered clinical practice, resistance, cumulative toxicity, and heterogeneous HER2 expression continue to limit sustained efficacy.
yojanasewa.com
February 1, 2026 at 7:32 PM
GSK5764227 (HS-20093): Clinical development of next generation HER2-directed antibody drug conjugate
HER2 remains one of the most therapeutic oncogenic drivers in solid tumors, most prominent in breast and tumors. stomach cancerFurthermore, it is increasingly being found across a wider range of…
HER2 remains one of the most therapeutic oncogenic drivers in solid tumors, most prominent in breast and tumors. stomach cancerFurthermore, it is increasingly being found across a wider range of…
EBV is oncogenic and the cause of multiple sclerosis. They’ll keep putting out papers to ignore the fact that you cannot have MS or Nasopharyngeal carcinoma without having had mononucleosis or another EBV related infection. It’s tied to lymphomas, gastric cancers, lupus, rheumatoid arthritis…
February 1, 2026 at 4:35 PM
EBV is oncogenic and the cause of multiple sclerosis. They’ll keep putting out papers to ignore the fact that you cannot have MS or Nasopharyngeal carcinoma without having had mononucleosis or another EBV related infection. It’s tied to lymphomas, gastric cancers, lupus, rheumatoid arthritis…
This study demonstrates that PCED1B-AS1 expression is upregulated in #HepatocellularCarcinoma, exerting an #Oncogenic role by promoting HCC cell proliferation and invasion via the miR-34a/CD44 axis. #Medsky
Read more: doi.org/10.1007/s115...
Read more: doi.org/10.1007/s115...
January 31, 2026 at 9:55 AM
This study demonstrates that PCED1B-AS1 expression is upregulated in #HepatocellularCarcinoma, exerting an #Oncogenic role by promoting HCC cell proliferation and invasion via the miR-34a/CD44 axis. #Medsky
Read more: doi.org/10.1007/s115...
Read more: doi.org/10.1007/s115...
COVID is a vascular disease. It can invade any organ with an ACE-2 receptor including your brain. It activates latent viruses like EBV and HPV and dysregulates your immune system. It massively increases your risk of stroke and there’s some evidence it’s oncogenic. Grow the hell up and wear a mask
January 30, 2026 at 7:27 PM
COVID is a vascular disease. It can invade any organ with an ACE-2 receptor including your brain. It activates latent viruses like EBV and HPV and dysregulates your immune system. It massively increases your risk of stroke and there’s some evidence it’s oncogenic. Grow the hell up and wear a mask
Insider Post
one thing that really infuriated experts about Duesberg is that this was the 2nd time he had made this mistake; iirc, the 1st time was about another oncogenic virus
and Duesberg got roasted by Baltimore, iirc
one thing that really infuriated experts about Duesberg is that this was the 2nd time he had made this mistake; iirc, the 1st time was about another oncogenic virus
and Duesberg got roasted by Baltimore, iirc
January 30, 2026 at 1:34 PM
Insider Post
one thing that really infuriated experts about Duesberg is that this was the 2nd time he had made this mistake; iirc, the 1st time was about another oncogenic virus
and Duesberg got roasted by Baltimore, iirc
one thing that really infuriated experts about Duesberg is that this was the 2nd time he had made this mistake; iirc, the 1st time was about another oncogenic virus
and Duesberg got roasted by Baltimore, iirc
Reading the research around oncogenic HPV strains for a class discussion, I was really struck by the wonder of the vaccine.
There are over 400 identified strains of HPV, and some of them are oncogenic, meaning they cause cancer. The vaccine flatly defeats many of them. It is really magical.
There are over 400 identified strains of HPV, and some of them are oncogenic, meaning they cause cancer. The vaccine flatly defeats many of them. It is really magical.
HPV vaccine can also prevent other cancers caused by the virus, including head and neck and penile cancers. There is no credible evidence of harm.
January 30, 2026 at 1:29 PM
Reading the research around oncogenic HPV strains for a class discussion, I was really struck by the wonder of the vaccine.
There are over 400 identified strains of HPV, and some of them are oncogenic, meaning they cause cancer. The vaccine flatly defeats many of them. It is really magical.
There are over 400 identified strains of HPV, and some of them are oncogenic, meaning they cause cancer. The vaccine flatly defeats many of them. It is really magical.
#Comment🚨
Cat tumour viruses mirror human oncogenic viruses. Beatty & Tu argue that comparative oncology in cats could accelerate prevention and treatment strategies for viral cancers.
📖⬇️
http://dlvr.it/TQdk2t
Cat tumour viruses mirror human oncogenic viruses. Beatty & Tu argue that comparative oncology in cats could accelerate prevention and treatment strategies for viral cancers.
📖⬇️
http://dlvr.it/TQdk2t
January 29, 2026 at 4:35 PM
#Comment🚨
Cat tumour viruses mirror human oncogenic viruses. Beatty & Tu argue that comparative oncology in cats could accelerate prevention and treatment strategies for viral cancers.
📖⬇️
http://dlvr.it/TQdk2t
Cat tumour viruses mirror human oncogenic viruses. Beatty & Tu argue that comparative oncology in cats could accelerate prevention and treatment strategies for viral cancers.
📖⬇️
http://dlvr.it/TQdk2t
Research into KSHV's oncogenic machinery reveals new pathways for next-generation diagnostics and therapies.
🔗 Source: https://pubmed.ncbi.nlm.nih.gov/41563473/%22
🔗 Source: https://pubmed.ncbi.nlm.nih.gov/41563473/%22
January 29, 2026 at 7:59 AM
Research into KSHV's oncogenic machinery reveals new pathways for next-generation diagnostics and therapies.
🔗 Source: https://pubmed.ncbi.nlm.nih.gov/41563473/%22
🔗 Source: https://pubmed.ncbi.nlm.nih.gov/41563473/%22
Online now: Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers
Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers
Wang et al. systematically annotate orphan non-coding RNAs (oncRNAs), cancer-emergent small RNAs, across 32 cancers. The study demonstrates that oncRNAs are informative of cancer types and have functional roles in cancer progression. Importantly, circulating oncRNAs are predictive of clinical outcomes in breast cancer patients, holding potential for liquid biopsy applications.
dlvr.it
January 28, 2026 at 8:20 PM
Online now: Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers
Tragic. I hope this family gets the genetic counseling they need- there are preventative screening guidelines for known oncogenic mutations that could spare other family members from this suffering.
January 28, 2026 at 7:40 PM
Tragic. I hope this family gets the genetic counseling they need- there are preventative screening guidelines for known oncogenic mutations that could spare other family members from this suffering.
Homeodomain-driven oncogenic diversion to a TCRγδ phenotype in T-cell Acute Lymphoblastic Leukemia
#gdTcells @bloodjournals.hematology.org
#gdTcells @bloodjournals.hematology.org
Homeodomain-driven oncogenic diversion to a TCRγδ phenotype in T-cell Acute Lymphoblastic Leukemia
Key Points. The vast majority of TCRγδ+ T-ALLs express homeodomain-containing (HD+) oncogenes and display features of pre-αβ cortical thymocytes.Overexpres
ashpublications.org
January 28, 2026 at 4:01 PM
Homeodomain-driven oncogenic diversion to a TCRγδ phenotype in T-cell Acute Lymphoblastic Leukemia
#gdTcells @bloodjournals.hematology.org
#gdTcells @bloodjournals.hematology.org
Combining degraders targeting p300 and SWI/SNF:
🧬 Strong synergy in SS18–SSX–positive cells
🧬 Profound loss of SS18–SSX chromatin binding
🧬 Broad collapse of oncogenic gene expression
🧬 Dramatic loss of cell viability
🧬 Strong synergy in SS18–SSX–positive cells
🧬 Profound loss of SS18–SSX chromatin binding
🧬 Broad collapse of oncogenic gene expression
🧬 Dramatic loss of cell viability
January 28, 2026 at 9:54 AM
Combining degraders targeting p300 and SWI/SNF:
🧬 Strong synergy in SS18–SSX–positive cells
🧬 Profound loss of SS18–SSX chromatin binding
🧬 Broad collapse of oncogenic gene expression
🧬 Dramatic loss of cell viability
🧬 Strong synergy in SS18–SSX–positive cells
🧬 Profound loss of SS18–SSX chromatin binding
🧬 Broad collapse of oncogenic gene expression
🧬 Dramatic loss of cell viability
To recap:
Remove SWI/SNF ➡️ Modest effects on SS18-SSX binding
Remove p300 ➡️ Major loss of SS18-SSX occupancy and transcription
❗ P300, not SWI/SNF, sustains the oncogenic program
Remove SWI/SNF ➡️ Modest effects on SS18-SSX binding
Remove p300 ➡️ Major loss of SS18-SSX occupancy and transcription
❗ P300, not SWI/SNF, sustains the oncogenic program
January 28, 2026 at 9:54 AM
To recap:
Remove SWI/SNF ➡️ Modest effects on SS18-SSX binding
Remove p300 ➡️ Major loss of SS18-SSX occupancy and transcription
❗ P300, not SWI/SNF, sustains the oncogenic program
Remove SWI/SNF ➡️ Modest effects on SS18-SSX binding
Remove p300 ➡️ Major loss of SS18-SSX occupancy and transcription
❗ P300, not SWI/SNF, sustains the oncogenic program
Even when SWI/SNF activity is broadly eliminated:
🧬 Oncogenic transcription does not shut down
🧬 SS18-SSX transcriptional activity persists
➡️ Conclusion: SWI/SNF is not the main engine of SS18-SSX driven transcription
🧬 Oncogenic transcription does not shut down
🧬 SS18-SSX transcriptional activity persists
➡️ Conclusion: SWI/SNF is not the main engine of SS18-SSX driven transcription
January 28, 2026 at 9:54 AM
Even when SWI/SNF activity is broadly eliminated:
🧬 Oncogenic transcription does not shut down
🧬 SS18-SSX transcriptional activity persists
➡️ Conclusion: SWI/SNF is not the main engine of SS18-SSX driven transcription
🧬 Oncogenic transcription does not shut down
🧬 SS18-SSX transcriptional activity persists
➡️ Conclusion: SWI/SNF is not the main engine of SS18-SSX driven transcription
Clinical efforts to target SWI/SNF (e.g. BRD9 degraders, based on our previous discoveries) have shown limited and transient benefits in synovial sarcoma patients.
So, we asked a simple question:
👉 Does SS18-SSX actually need SWI/SNF to drive oncogenic transcription?
So, we asked a simple question:
👉 Does SS18-SSX actually need SWI/SNF to drive oncogenic transcription?
January 28, 2026 at 9:54 AM
Clinical efforts to target SWI/SNF (e.g. BRD9 degraders, based on our previous discoveries) have shown limited and transient benefits in synovial sarcoma patients.
So, we asked a simple question:
👉 Does SS18-SSX actually need SWI/SNF to drive oncogenic transcription?
So, we asked a simple question:
👉 Does SS18-SSX actually need SWI/SNF to drive oncogenic transcription?
SS18-SSX co-opts P300 to sustain oncogenic transcription independent of SWI/SNF activity https://www.biorxiv.org/content/10.64898/2026.01.26.701706v1
January 28, 2026 at 4:47 AM
SS18-SSX co-opts P300 to sustain oncogenic transcription independent of SWI/SNF activity https://www.biorxiv.org/content/10.64898/2026.01.26.701706v1
SS18-SSX co-opts P300 to sustain oncogenic transcription independent of SWI/SNF activity https://www.biorxiv.org/content/10.64898/2026.01.26.701706v1
January 28, 2026 at 4:47 AM
SS18-SSX co-opts P300 to sustain oncogenic transcription independent of SWI/SNF activity https://www.biorxiv.org/content/10.64898/2026.01.26.701706v1
Advances in molecular pathology and therapy of non-small cell lung cancer
An in-depth overview of NSCLC molecular pathology, oncogenic drivers, targeted therapies, and resistance mechanisms.
doi.org/10.1038/s413...
#NSCLC #MolecularPathology #TargetedTherapy #PrecisionOncology
An in-depth overview of NSCLC molecular pathology, oncogenic drivers, targeted therapies, and resistance mechanisms.
doi.org/10.1038/s413...
#NSCLC #MolecularPathology #TargetedTherapy #PrecisionOncology
January 27, 2026 at 10:33 AM
Advances in molecular pathology and therapy of non-small cell lung cancer
An in-depth overview of NSCLC molecular pathology, oncogenic drivers, targeted therapies, and resistance mechanisms.
doi.org/10.1038/s413...
#NSCLC #MolecularPathology #TargetedTherapy #PrecisionOncology
An in-depth overview of NSCLC molecular pathology, oncogenic drivers, targeted therapies, and resistance mechanisms.
doi.org/10.1038/s413...
#NSCLC #MolecularPathology #TargetedTherapy #PrecisionOncology
Advances in molecular pathology and therapy of non-small cell lung cancer
An in-depth overview of NSCLC molecular pathology, oncogenic drivers, targeted therapies, and resistance mechanisms.
doi.org/10.1038/s413...
#NSCLC #MolecularPathology #TargetedTherapy #PrecisionOncology
An in-depth overview of NSCLC molecular pathology, oncogenic drivers, targeted therapies, and resistance mechanisms.
doi.org/10.1038/s413...
#NSCLC #MolecularPathology #TargetedTherapy #PrecisionOncology
January 27, 2026 at 10:33 AM
Advances in molecular pathology and therapy of non-small cell lung cancer
An in-depth overview of NSCLC molecular pathology, oncogenic drivers, targeted therapies, and resistance mechanisms.
doi.org/10.1038/s413...
#NSCLC #MolecularPathology #TargetedTherapy #PrecisionOncology
An in-depth overview of NSCLC molecular pathology, oncogenic drivers, targeted therapies, and resistance mechanisms.
doi.org/10.1038/s413...
#NSCLC #MolecularPathology #TargetedTherapy #PrecisionOncology
This is but one of many articles exploring SARS-CoV-2’s potential oncogenic properties. If you want to avoid cancer, take steps to avoid C-19. If you don’t think your ‘future you’ will be glad you did, you’ve clearly never had cancer. It’s rather unpleasant.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
The double-edged sword: How SARS-CoV-2 might fuel lung cancer: Investigating the potential oncogenic mechanisms of the novel coronavirus in lung carcinogenesis
The COVID-19 pandemic, caused by SARS-CoV-2, has had far-reaching consequences beyond acute respiratory illness, with growing evidence suggesting pote…
www.sciencedirect.com
January 25, 2026 at 7:06 PM
This is but one of many articles exploring SARS-CoV-2’s potential oncogenic properties. If you want to avoid cancer, take steps to avoid C-19. If you don’t think your ‘future you’ will be glad you did, you’ve clearly never had cancer. It’s rather unpleasant.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
They then asked whether any oncRNAs actually drive disease.
Large-scale functional screens in mice showed ~5% have clear oncogenic activity, with two breast cancer oncRNAs found to promote increased tumor growth and metastasis.
Large-scale functional screens in mice showed ~5% have clear oncogenic activity, with two breast cancer oncRNAs found to promote increased tumor growth and metastasis.
January 23, 2026 at 5:38 PM
They then asked whether any oncRNAs actually drive disease.
Large-scale functional screens in mice showed ~5% have clear oncogenic activity, with two breast cancer oncRNAs found to promote increased tumor growth and metastasis.
Large-scale functional screens in mice showed ~5% have clear oncogenic activity, with two breast cancer oncRNAs found to promote increased tumor growth and metastasis.
Join us for #Pathology Grand Rounds on Thursday, Jan. 29 at 12:30 PM ET as Guang-Yu Yang, MD, PhD, Professor & Chair of #Pathology at Virginia Commonwealth University School of Medicine, presents on, “Breaking the Oncogenic Circuit” @yaleschoolofmed.bsky.social shorturl.at/wQ1Ng
January 23, 2026 at 2:16 PM
Join us for #Pathology Grand Rounds on Thursday, Jan. 29 at 12:30 PM ET as Guang-Yu Yang, MD, PhD, Professor & Chair of #Pathology at Virginia Commonwealth University School of Medicine, presents on, “Breaking the Oncogenic Circuit” @yaleschoolofmed.bsky.social shorturl.at/wQ1Ng
Julien Debbache, Lukas Sommer & co generated a novel sporadic #MouseModel of Nf1 wild-type malignant peripheral nerve sheath tumours, driven by conditional expression of oncogenic BrafV600E and loss of Pten in the glial lineage.
#sarcoma
Read doi.org/10.1242/dmm....
#sarcoma
Read doi.org/10.1242/dmm....
January 23, 2026 at 8:01 AM
Julien Debbache, Lukas Sommer & co generated a novel sporadic #MouseModel of Nf1 wild-type malignant peripheral nerve sheath tumours, driven by conditional expression of oncogenic BrafV600E and loss of Pten in the glial lineage.
#sarcoma
Read doi.org/10.1242/dmm....
#sarcoma
Read doi.org/10.1242/dmm....